Dr. Jabbour is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
211 S 9th St, Ste 600
Philadelphia, PA 19107Phone+1 215-955-1925Fax+1 215-928-3160
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 1999
- Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1994 - 1997
- St Joseph's University Medical SchoolClass of 1993
- La Sagesse CollegeBachelors, Experimental Sciences, 1983 - 1986
Certifications & Licensure
- PA State Medical License 1997 - 2024
- FL State Medical License 2021 - 2023
- NJ State Medical License 1999 - 2003
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Philadelphia Magazine Castle Connolly, 2011-2015
- Top Doctor in Endocrinology South Jersey Magazine, 2013
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
- Join now to see all
Clinical Trials
- Dapagliflozin DPPIV Inhibitor add-on Study Start of enrollment: 2009 Oct 01
- A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
- Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight Start of enrollment: 2015 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsSGLT2 inhibitors.I Dardi, T Kouvatsos, S A Jabbour
Biochemical Pharmacology. 2016-02-01 - 171 citationsEfficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter A. Senior, Christoph Hasslacher
Diabetes Care. 2018-07-18 - 5 citationsAssessing the impact of medically tailored meals and medical nutrition therapy on type 2 diabetes: Protocol for Project MiNT.Kristin L. Rising, Mackenzie Kemp, Patricia Davidson, Judd E. Hollander, Serge Jabbour
Contemporary Clinical Trials. 2021-07-24
Journal Articles
- Safety and Efficacy of Exenatide Once Weekly plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Contro...Serge Jabbour, MD, Diabetes Care
- An Open Label Randomized Phase II Study of Pasireotide With or Without Everolimus in Castrate-Resistant Chemotherapy-Naïve Prostate Cancer PatientsLin J, Deng A, Hoffman-Censits J, Gibney G, Hyslop T, Miller B, Kilpatrick D, Jabbour S, Kelly WK, Cancer Treatment Communications, 1/1/2015
- Incidence and Severity of Pancreatogenic Diabetes after Pancreatic ResectionBurkhart RA, Gerber SM, Tholey RM, Lamb KM, Somasundaram A, McIntyre CA, Fradkin EC, Ashok AP, Felte RF, Mehta JM, Rosato EL, Lavu H, Jabbour SA, Yeo CJ, and Winter JM, Journal of Gastrointestinal Surgery, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Robust Dose-dependent Glucose Lowering and Body Weight (BW) Reductions with the Novel Oral Formulation of Semaglutide in Patients with early Type 2 Diabetes (T2D)Jabbour S, Pieber T, Rosenstock J, Hartoft-Nielsen ML, Højbjerg Hansen OK, Davies M, The Endocrine Society, Boston, MA, 1/1/2016
- Patient characteristics and real world effectiveness of dapagliflozin; an observational analysis of US electronic health recordsJabbour S, Bell K, Eudicone J, Shatskov A, Katz A, WCIR, 13th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, Los Angeles, CA, 1/1/2015
- Incidence of Radioiodine-induced Gastritis and the Dosage of I-131 Ablation for Differentiated Thyroid Cancer: Results of a Multi-year AnalysisIntenzo C, Jabbour SA, Miller J, Kim S, Furlong K, Ahmed I, SNMMI (Society of Nuclear Medicine and Molecular Aging) Annual Meeting, Baltimore, MD, 1/1/2015
- Join now to see all
Lectures
- Guideline-Based Approach to Manage T2DM: Place of SGLT2-InhibitorsLucknow, India - 1/31/2015
- Improving the Metabolic State in T2DM Patients & Associated RisksLucknow, India - 1/29/2015
- Glucocorticoids and HPA Axis SuppressionPhiladelphia, PA - 1/24/2015
- Join now to see all
Other
- Modern Oral Agents in Clinical Practice: Where do SGLT2 Inhibitors FitJabbour SA, Medscape
http://www.medscape.org/viewarticle/833998
1/1/2014 - Clinical Decision Support: DermatologyBoban I, Jabbour SA
1/1/2012 - Syndrome XJabbour SA, Miller JL, World Book, Inc.
www.worldbookonline.com
1/21/2004 - Join now to see all
Press Mentions
- COVID-19 and Diabetes, What You Need to KnowOctober 29th, 2021
- Combo Drug Treatment for Type 2 Diabetes Remains Effective After Two YearsNovember 2nd, 2020
- Clinical Endocrinology Update Goes Bicoastal for a Second YearJuly 30th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: